PURPOSE: To determine the frequency and volume of seroma after breast-conserving surgery (BCS) with or without intraoperative radiotherapy (IORT). METHODS AND MATERIALS: Seventy-one patients with 73 breast cancers (IORT group) treated with IORT (20 Gy Intrabeam) as a boost during BCS were compared with 86 patients with 88 breast tumors (NO-IORT group) treated without IORT. Clinical examination and measurement of seroma volume on treatment-planning CT (CT-seroma) was done at median interval of 35 days after BCS. RESULTS: Seroma were found on palpation in 37 patients (23%) and on CT in 105 patients (65%; median volume, 26.3 mL). Interval between BCS and CT was significantly shorter in patients with palpable seroma (median, 33 days) or CT-seroma (33 days) compared with those with no palpable seroma (36.5 days; p = 0.027) or CT-seroma (52 days, p < 0.001). The rate of palpable seroma was not different (IORT n = 17, 23%; NO-IORT n = 20, 23%; p = 0.933), whereas fewer patients required puncture in the IORT group [3 (4%) vs. 10 (11%)]. In contrast, more patients showed CT-seroma after IORT (IORT n = 59, 81%; NO-IORT n = 46, 52%; p < 0.001). The interval between BCS and CT was significantly shorter in patients with IORT as compared with the NO-IORT patients (median, 33 days vs. 41.5 days; p = 0.036). CONCLUSION: Intraoperative radiotherapy with low-kilovoltage X-rays during BCS is not associated with an increased rate of palpable seroma or seroma requiring treatment. The rate of seroma formation on CT was higher after IORT compared with the NO-IORT group, which might be because of the shorter interval between BCS and CT. Copyright 2010 Elsevier Inc. All rights reserved.
PURPOSE: To determine the frequency and volume of seroma after breast-conserving surgery (BCS) with or without intraoperative radiotherapy (IORT). METHODS AND MATERIALS: Seventy-one patients with 73 breast cancers (IORT group) treated with IORT (20 Gy Intrabeam) as a boost during BCS were compared with 86 patients with 88 breast tumors (NO-IORT group) treated without IORT. Clinical examination and measurement of seroma volume on treatment-planning CT (CT-seroma) was done at median interval of 35 days after BCS. RESULTS:Seroma were found on palpation in 37 patients (23%) and on CT in 105 patients (65%; median volume, 26.3 mL). Interval between BCS and CT was significantly shorter in patients with palpable seroma (median, 33 days) or CT-seroma (33 days) compared with those with no palpable seroma (36.5 days; p = 0.027) or CT-seroma (52 days, p < 0.001). The rate of palpable seroma was not different (IORT n = 17, 23%; NO-IORT n = 20, 23%; p = 0.933), whereas fewer patients required puncture in the IORT group [3 (4%) vs. 10 (11%)]. In contrast, more patients showed CT-seroma after IORT (IORT n = 59, 81%; NO-IORT n = 46, 52%; p < 0.001). The interval between BCS and CT was significantly shorter in patients with IORT as compared with the NO-IORT patients (median, 33 days vs. 41.5 days; p = 0.036). CONCLUSION: Intraoperative radiotherapy with low-kilovoltage X-rays during BCS is not associated with an increased rate of palpable seroma or seroma requiring treatment. The rate of seroma formation on CT was higher after IORT compared with the NO-IORT group, which might be because of the shorter interval between BCS and CT. Copyright 2010 Elsevier Inc. All rights reserved.
Authors: F A Calvo; C V Sole; M E González; E D Tangco; J López-Tarjuelo; I Koubychine; J A Santos; J Pascau; R Herranz; C Ferrer Journal: Clin Transl Oncol Date: 2013-03-05 Impact factor: 3.405
Authors: Sandra D Scherer; Jochen Bauer; Anja Schmaus; Christian Neumaier; Carsten Herskind; Marlon R Veldwijk; Frederik Wenz; Jonathan P Sleeman Journal: PLoS One Date: 2016-09-02 Impact factor: 3.240
Authors: Jayant Sharad Vaidya; Uma Jayant Vaidya; Michael Baum; Max Kishor Bulsara; David Joseph; Jeffrey S Tobias Journal: Front Oncol Date: 2022-08-11 Impact factor: 5.738
Authors: Benjamin Tuschy; Sebastian Berlit; Simone Romero; Elena Sperk; Frederik Wenz; Sven Kehl; Marc Sütterlin Journal: Radiat Oncol Date: 2013-04-22 Impact factor: 3.481
Authors: Christine Chin; Priya Jadeja; Bret Taback; David P Horowitz; Sheldon M Feldman; Richard Ha; Eileen P Connolly Journal: Front Oncol Date: 2017-08-28 Impact factor: 6.244